Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2019 | Editorial Commentary

FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future

Authors: Abdullah Al-Zaghal, William Y. Raynor, Siavash Mehdizadeh Seraj, Thomas J. Werner, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2019

Excerpt

Fever of unknown origin (FUO) remains one of the most difficult diagnostic challenges frequently encountered by clinicians. It is defined as fever of 38.3 °C (101 °F) or higher for at least 3 weeks in immunocompetent, otherwise healthy patients with no identified cause of fever after undergoing a set of obligatory investigations [1]. …

Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961;40:1–30.CrossRef

Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med. 2002;32:2–5. https://doi.org/10.1053/snuc.2002.29269.CrossRefPubMed

Patronas NJ, Brooks RA, DeLaPaz RL, Smith BH, Kornblith PL, Di Chiro G. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol. 1983;4:533–5.PubMedPubMedCentral

Warburg O. On the origin of cancer cells. Science (New York, NY). 1956;123:309–14.CrossRef

Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med. 1994;35:1650–2.PubMed

Larson SM. Cancer or inflammation? A Holy Grail for nuclear medicine. J Nucl Med. 1994;35:1653–5.PubMed

Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59. https://doi.org/10.1053/snuc.2002.29278.CrossRefPubMed

Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009;39:124–45. https://doi.org/10.1053/j.semnuclmed.2008.10.006.CrossRefPubMed

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–79.PubMed

10.

Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36(Suppl 1):S113–20. https://doi.org/10.1007/s00259-008-0951-6.CrossRefPubMed

11.

Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med. 2009;39:36–51. https://doi.org/10.1053/j.semnuclmed.2008.08.004.CrossRefPubMed

12.

Alavi A, Werner TJ. FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future. Eur J Nucl Med Mol Imaging. 2017;44:417–20. https://doi.org/10.1007/s00259-016-3606-z.CrossRefPubMed

13.

Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown origin. Clin Med (Lond). 2015;15:280–4. https://doi.org/10.7861/clinmedicine.15-3-280.CrossRef

14.

Bandyopadhyay D, Bandyopadhyay R, Paul R, Roy D. Etiological study of Fever of unknown origin in patients admitted to medicine ward of a teaching hospital of eastern India. J Global Infect Dis. 2011;3:329–33. https://doi.org/10.4103/0974-777X.91052.CrossRef

15.

Liu KS, Sheng WH, Chen YC, Chang SC, Hsieh WC. Fever of unknown origin: a retrospective study of 78 adult patients in Taiwan. J Microbiol Immunol Infect. 2003;36:243–7.CrossRefPubMed

16.

Tabak F, Mert A, Celik AD, Ozaras R, Altiparmak MR, Ozturk R, et al. Fever of unknown origin in Turkey. Infection. 2003;31:417–20. https://doi.org/10.1007/s15010-003-3040-6.CrossRefPubMed

17.

Ankrah AO, Glaudemans A, Maes A, Van de Wiele C, Dierckx R, Vorster M, et al. Tuberculosis. Semin Nucl Med. 2018;48:108–30. https://doi.org/10.1053/j.semnuclmed.2017.10.005.CrossRefPubMed

18.

Besson FL, Chaumet-Riffaud P, Playe M, Noel N, Lambotte O, Goujard C, et al. Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43:1887–95. https://doi.org/10.1007/s00259-016-3377-6.CrossRefPubMed

19.

Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004;31:29–37. https://doi.org/10.1007/s00259-003-1338-3.CrossRefPubMed

20.

Hot A, Schmulewitz L, Viard JP, Lortholary O. Fever of unknown origin in HIV/AIDS patients. Infect Dis Clin N Am. 2007;21:1013–32, ix. https://doi.org/10.1016/j.idc.2007.08.003.CrossRef

21.

Castaigne C, Tondeur M, de Wit S, Hildebrand M, Clumeck N, Dusart M. Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study. Nucl Med Commun. 2009;30:41–7.CrossRefPubMed

22.

Martin C, Castaigne C, Tondeur M, Flamen P, De Wit S. Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study. HIV Med. 2013;14:455–62. https://doi.org/10.1111/hiv.12030.CrossRefPubMed

23.

Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:1348–55. https://doi.org/10.1007/s00259-012-2143-7.CrossRefPubMed

24.

Vos FJ, Donnelly JP, Oyen WJ, Kullberg BJ, Bleeker-Rovers CP, Blijlevens NM. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:120–8. https://doi.org/10.1007/s00259-011-1939-1.CrossRefPubMed

25.

Kouijzer IJE, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJG. Fever of Unknown Origin: the Value of FDG-PET/CT. Semin Nucl Med. 2018;48:100–7. https://doi.org/10.1053/j.semnuclmed.2017.11.004.CrossRefPubMed

26.

Hess S, Alavi A, Basu S. PET-Based Personalized Management of Infectious and Inflammatory Disorders. PET Clin. 2016;11:351–61. https://doi.org/10.1016/j.cpet.2016.02.008.CrossRefPubMed

27.

Lee SW, Kim SJ, Seo Y, Jeong SY, Ahn BC, Lee J. F-18 FDG PET for assessment of disease activity of large vessel vasculitis: A systematic review and meta-analysis. J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-018-1406-5.

28.

Vaidyanathan S, Chattopadhyay A, Mackie SL, Scarsbrook AF. Comparative effectiveness of (18)F-FDG PET-CT and contrast-enhanced CT in the diagnosis of suspected large-vessel vasculitis. Br J Radiol. 2018;91:20180247. https://doi.org/10.1259/bjr.20180247.CrossRefPubMedPubMedCentral

29.

Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94:e622. https://doi.org/10.1097/MD.0000000000000622.CrossRefPubMedPubMedCentral

30.

Takahashi H, Yamashita H, Kubota K, Miyata Y, Okasaki M, Morooka M, et al. Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol. 2015;25:546–51. https://doi.org/10.3109/14397595.2014.978936.CrossRefPubMed

31.

Wakura D, Kotani T, Takeuchi T, Komori T, Yoshida S, Makino S, et al. Differentiation between Polymyalgia Rheumatica (PMR) and Elderly-Onset Rheumatoid Arthritis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Is Enthesitis a New Pathological Lesion in PMR? PLoS One. 2016;11:e0158509. https://doi.org/10.1371/journal.pone.0158509.CrossRefPubMedPubMedCentral

32.

Al-Zaghal A, Raynor W, Khosravi M, Guermazi A, Werner TJ, Alavi A. Applications of PET Imaging in the Evaluation of Musculoskeletal Diseases Among the Geriatric Population. Semin Nucl Med. 2018. https://doi.org/10.1053/j.semnuclmed.2018.07.002.CrossRefPubMed

33.

Petersdorf RG. Fever of unknown origin. An old friend revisited. Arch Intern Med. 1992;152:21–2.CrossRefPubMed

34.

Kaya A, Ergul N, Kaya SY, Kilic F, Yilmaz MH, Besirli K, et al. The management and the diagnosis of fever of unknown origin. Expert Rev Anti-Infect Ther. 2013;11:805–15. https://doi.org/10.1586/14787210.2013.814436.CrossRefPubMed

35.

Roca Campana V, Rodriguez Silva H. Malignant lymphomas presenting as fever of unknown origin. An Med Interna. 2007;24:531–4.PubMed

36.

Salih SB, Saeed AB, Alzahrani M, Al Qahtani M, Haider A, Palker V. Primary CNS lymphoma presenting as fever of unknown origin. J Neuro-Oncol. 2009;93:401–4. https://doi.org/10.1007/s11060-008-9777-0.CrossRef

37.

Casallo Blanco S, de Matias Salces L, Marcos Sanchez F, Martin Barranco MJ, Nunez Cuerda E, Solano Ramos F. Colon lymphoma as a cause of fever of unknown origin. An Med Interna. 2006;23:379–81.PubMed

38.

Zeidman A, Horowitz A, Fradin Z, Cohen A, Wolfson L, Elimelech O. Fulminant intravascular lymphoma presenting as fever of unknown origin. Leuk Lymphoma. 2004;45:1691–3. https://doi.org/10.1080/10428190410001683750.CrossRefPubMed

39.

Landman RE, Wardlaw SL, McConnell RJ, Khandji AG, Bruce JN, Freda PU. Pituitary lymphoma presenting as fever of unknown origin. J Clin Endocrinol Metab. 2001;86:1470–6. https://doi.org/10.1210/jcem.86.4.7389.CrossRefPubMed

40.

Muller N, Kessler R, Caillard S, Epailly E, Hubele F, Heimburger C, et al. (18)F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation. Nucl Med Mol Imaging. 2017;51:58–68. https://doi.org/10.1007/s13139-016-0461-6.CrossRefPubMed

41.

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369–79.CrossRefPubMedPubMedCentral

42.

Houshmand S, Salavati A, Segtnan EA, Grupe P, Hoilund-Carlsen PF, Alavi A. Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings. PET Clin. 2016;11:65–84. https://doi.org/10.1016/j.cpet.2015.07.003.CrossRefPubMed

43.

Bharucha T, Rutherford A, Skeoch S, Alavi A, Brown M, Galloway J. group F-PCifouow. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clin Radiol. 2017;72:764–71. https://doi.org/10.1016/j.crad.2017.04.014.CrossRefPubMed

44.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66. https://doi.org/10.1148/radiol.12111148.CrossRefPubMed

45.

Nakachi S, Okada M, Morishima S, Agarie Y, Kitamura S, Uchibori S, et al. Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia. Hematology. 2017;22:536–43. https://doi.org/10.1080/10245332.2017.1312088.CrossRefPubMed

46.

Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7. https://doi.org/10.1182/blood-2012-12-473389.CrossRefPubMed

47.

Arslan F, Yilmaz M, Cakir T, Mert A. Significant contribution of Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in a case of acute lymphoblastic leukemia presenting with fever of unknown origin. Intern Med. 2014;53:789–91.CrossRefPubMed

48.

Karunanithi S, Sharma P, Roy SG, Vettiyil B, Sharma A, Thulkar S, et al. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma. Clin Nucl Med. 2014;39:772–6. https://doi.org/10.1097/RLU.0000000000000523.CrossRefPubMed

49.

de Barros AB, Tsourkas A, Saboury B, Cardoso VN, Alavi A. Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res. 2012;2:39. https://doi.org/10.1186/2191-219x-2-39.CrossRefPubMedPubMedCentral

50.

Wang Q, Li YM, Li Y, Hua FC, Wang QS, Zhang XL, et al. (18)F-FDGPET/CT in fever of unknown origin and inflammation of unknown origin: a Chinese multi-center study. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4121-1.

51.

Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980–5. https://doi.org/10.2967/jnumed.108.054692.CrossRefPubMed

Title: FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future
Authors: Abdullah Al-Zaghal
William Y. Raynor
Siavash Mehdizadeh Seraj
Thomas J. Werner
Abass Alavi
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4164-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer

Correction to: Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

Target identification for the diagnosis and intervention of vulnerable atherosclerotic plaques beyond 18F-fluorodeoxyglucose positron emission tomography imaging: promising tracers on the horizon